A case report of intraoperative reflux and gastric contents retention induced by Liraglutide during the perioperative period of bariatric surgery

doi:10.3877/cma.j.issn.2095-9605.2026.01.011

Abstract

Abstract:

In recent years, with the rapid development of novel anti-obesity medications such as glucagon-like peptide-1 receptor agonists (GLP-1RA), these agents have been extensively utilized in the treatment of obesity, type 2 diabetes mellitus (T2DM), and various metabolic disorders. Currently, only a limited number of published studies have reported an increased risk of intraoperative regurgitation and aspiration when GLP-1RA is administered in the perioperative period. This paper presents a case involving a patient who fasted for more than 18 hours prior to surgery, experienced regurgitation during tracheal intubation, and underwent laparoscopic sleeve gastrectomy (LSG) with preservation of the gastric fundus after intraoperative exploration revealed residual gastric contents. The aim of this report is to enhance the management of GLP-1RA in the perioperative period, reduce associated risks, and standardize the conduct of bariatric surgery.

Key words: Liraglutide, Bariatric surgery, Sleeve gastrectomy, GLP-1RA, Intraoperative reflux, Gastric contents retention, Perioperative period

Xiongxiong Chen, Jianwu Xiong, Zongwen Shen, Lei Yang, Yingxu Li. A case report of intraoperative reflux and gastric contents retention induced by Liraglutide during the perioperative period of bariatric surgery[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2026, 12(01): 78-83.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2026.01.011

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2026/V12/I01/78

Figures/Tables 4

References 40

[1]	王勇, 梁辉, 张频, 等. 中国肥胖及代谢疾病外科治疗指南（2024版）[J]. 中国实用外科杂志, 2024, 44(8): 841-849.
[2]	Peterli R, Wölnerhanssen B K, Peters T, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity: The SM-BOSS Randomized Clinical Trial[J]. JAMA, 2018, 319(3): 255-265.
[3]	Salminen P, Helmiö M, Ovaska J, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial[J]. JAMA, 2018, 319(3): 241-254.
[4]	Bray G A, Kim K K, Wilding J P H. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation[J]. Obes Rev, 2017, 18(7): 715-723.
[5]	Mechanick J I, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures-2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists[J]. Surg Obes Relat Dis, 2020, 16(2): 175-247.
[6]	Eisenberg D, Shikora S A, Aarts E, et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery [J]. Obes Surg, 2023, 33(1): 15-16.
[7]	Elmaleh-Sachs A, Schwartz J L, Bramante C T, et al. Obesity Management in Adults: A Review[J]. JAMA, 2023, 330(20): 2000-2015.
[8]	中国医师协会外科医师分会肥胖和代谢病外科专家工作组, 中国医师协会外科医师分会肥胖代谢外科综合管理专家工作组, 中国肥胖代谢外科研究协作组. 中国肥胖代谢外科数据库: 2023年度报告[J]. 中华肥胖与代谢病电子杂志, 2024, 10(2): 73-83.
[9]	中国医师协会外科医师分会肥胖和糖尿病外科医师委员会. 腹腔镜袖状胃切除术操作指南（2018版）[J]. 中华肥胖与代谢病电子杂志, 2018, 04(4): 196-201.
[10]	Huang R, Ding X, Fu H, Cai Q. Potential mechanisms of sleeve gastrectomy for reducing weight and improving metabolism in patients with obesity[J]. Surg Obes Relat Dis, 2019, 15(10): 1861-1871.
[11]	中国研究型医院学会糖尿病与肥胖外科专业委员会. 减重与代谢外科加速康复外科原则中国专家共识（2021版）[J]. 中华肥胖与代谢病电子杂志, 2021, 07(3): 141-145.
[12]	Noria S F, Shelby R D, Atkins K D, et al. Weight Regain After Bariatric Surgery: Scope of the Problem, Causes, Prevention, and Treatment[J]. Curr Diab Rep, 2023, 23(3): 31-42.
[13]	Milder D A, Milder T Y, Liang S S, Kam P C A. Glucagon-like peptide-1 receptor agonists: a narrative review of clinical pharmacology and implications for peri-operative practice[J]. Anaesthesia, 2024, 79(7): 735-747.
[14]	Drucker D J. GLP-1 physiology informs the pharmacotherapy of obesity[J]. Mol Metab, 2022, 57:101351.
[15]	Nolen-Doerr E, Stockman M C, Rizo I. Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity[J]. Curr Obes Rep, 2019, 8(3): 284-291.
[16]	Boer G A, Hay D L, Tups A. Obesity pharmacotherapy: incretin action in the central nervous system[J]. Trends Pharmacol Sci, 2023, 44(1): 50-63.
[17]	Muñoz M P S, Blandón J D R, Gutierrez I S C, et al. Liraglutide effectiveness in preoperative weight-loss for patients with severe obesity undergoing bariatric-metabolic surgery[J]. Updates Surg, 2024, 76(6): 2277-2283.
[18]	Wilmington R, Ardavani A, Simenacz A, et al. Liraglutide 3.0 mg (Saxenda^©) for Weight Loss and Remission of Pre-Diabetes. Real-World Clinical Evaluation of Effectiveness among Patients Awaiting Bariatric Surgery[J]. Obes Surg, 2024, 34(1): 286-289.
[19]	Stenberg E, Dos Reis Falcão L F, O'Kane M, et al. Guidelines for Perioperative Care in Bariatric Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations: A 2021 Update[J]. World J Surg, 2022, 46(4): 729-751.
[20]	Giordano S, Victorzon M. The impact of preoperative weight loss before laparoscopic gastric bypass[J]. Obes Surg, 2014, 24(5): 669-674.
[21]	Van Nieuwenhove Y, Dambrauskas Z, Campillo-Soto A, et al. Preoperative very low-calorie diet and operative outcome after laparoscopic gastric bypass: a randomized multicenter study[J]. Arch Surg, 2011, 146(11): 1300-1305.
[22]	Lucocq J, Homyer K, Geropoulos G, et al. Long-Term Weight Loss and Comorbidity Resolution of Laparoscopic Sleeve Gastrectomy and Laparoscopic Roux-en-Y Gastric Bypass and the Impact of Preoperative Weight Loss on Overall Outcome[J]. Surg Laparosc Endosc Percutan Tech, 2024, 34(5): 466-471.
[23]	曹晖, 陈亚进, 顾小萍, 等. 中国加速康复外科临床实践指南（2021版）[J]. 中国实用外科杂志, 2021, 41(9): 961-992.
[24]	Klein S R, Hobai I A. Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report[J]. Can J Anaesth, 2023, 70(8): 1394-1396.
[25]	Gulak M A, Murphy P. Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report[J]. Can J Anaesth, 2023, 70(8): 1397-1400.
[26]	Weber M, Siddarthan I, Mack P F. Clinically significant emesis in a patient taking a long-acting GLP-1 receptor agonist for weight loss[J]. Br J Anaesth, 2023, 131(2): e37-e39.
[27]	Wilson P R, Bridges K H, Wilson S H. Particulate Gastric Contents in Patients Prescribed Glucagon-Like Peptide 1 Receptor Agonists After Appropriate Perioperative Fasting: A Report of 2 Cases[J]. A A Pract, 2023, 17(8): e01712.
[28]	Dixit A A, Bateman B T, Hawn M T, et al. Preoperative GLP-1 Receptor Agonist Use and Risk of Postoperative Respiratory Complications[J]. JAMA, 2024, 331(19): 1672-1673.
[29]	Klonoff D C, Kim S H, Galindo R J, et al. Risks of peri- and postoperative complications with glucagon-like peptide-1 receptor agonists[J]. Diabetes Obes Metab, 2024, 26(8): 3128-3136.
[30]	Oprea A D, Umpierrez G E, Sweitzer B, Hepner D L. Perioperative Management of Patients Taking Glucagon-like Peptide-1 Receptor Agonists: Applying Evidence to Clinical Practice[J]. Anesthesiology, 2024, 141(6): 1141-1161.
[31]	Sherwin M, Hamburger J, Katz D, DeMaria S, Jr. Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide[J]. Can J Anaesth, 2023, 70(8): 1300-1306.
[32]	Friedrichsen M, Breitschaft A, Tadayon S, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity[J]. Diabetes Obes Metab, 2021, 23(3): 754-762.
[33]	Silveira S Q, da Silva L M, de Campos Vieira Abib A, et al. Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy[J]. J Clin Anesth, 2023, 87: 111091.
[34]	Sen S, Potnuru P P, Hernandez N, et al. Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia[J]. JAMA Surg, 2024, 159(6): 660-667.
[35]	Maselli D B, Camilleri M. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity[J]. Adv Exp Med Biol, 2021, 1307: 171-192.
[36]	Stark J E, Cole J L, Ghazarian R N, Klass M J. Impact of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) on Food Content During Esophagogastroduodenoscopy (EGD)[J]. Ann Pharmacother, 2022, 56(8):922-926.
[37]	Kobori T, Onishi Y, Yoshida Y, et al. Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy[J]. J Diabetes Investig, 2023, 14(6): 767-773.
[38]	Kindel T L, Wang A Y, Wadhwa A, et al. Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period[J]. Surg Obes Relat Dis, 2024, 20(12): 1183-1186.
[39]	Jones P M, Hobai I A, Murphy P M. Anesthesia and glucagon-like peptide-1 receptor agonists: proceed with caution![J]. Can J Anaesth, 2023, 70(8): 1281-1286.
[40]	Raven L M, Brown C, Greenfield J R. Considerations of delayed gastric emptying with peri-operative use of glucagon-like peptide-1 receptor agonists[J]. Med J Aust, 2024, 220(1): 14-16.

随访时间(月)	体重/kg	减重/kg	BMI(kg/m²)	%TWl(%)	%EWL(%)
1	156.5	21.5	47.78	12.08	22.33
3	133	45	40.60	25.28	46.81
6	122	56	37.24	31.46	58.27
8	117	61	35.71	34.27	63.48

随访时间(月)	体重/kg	减重/kg	BMI(kg/m²)	%TWl(%)	%EWL(%)
1	156.5	21.5	47.78	12.08	22.33
3	133	45	40.60	25.28	46.81
6	122	56	37.24	31.46	58.27
8	117	61	35.71	34.27	63.48

Please choose a citation manager

Content to export